GILBERTO DE CASTRO JUNIOR
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
conferenceObject Cancer patients with ECOG-PS higher than 1: Who are those who benefit of palliative chemotherapy?(2013) CAIRES-LIMA, Rafael; PROTASIO, Bruno Mendonca; CAIRES, Inacelli Queiroz de Souza; ROCHA, Lucila Soares Da Silva; OLIVEIRA, Julia Andrade De; GUERRA, Raquel Bezerra; MAK, Milena Perez; HOFF, Paulo M.; CASTRO, GilbertoconferenceObject Predicting adverse outcomes after cisplatin administration in head & neck and thoracic cancer(2013) BITTON, R. C.; CASTRIA, T. B.; AMARAL, A. A.; LOLLO, J. G.; SILVA, V. T. Costa e; BUDMANN, E.; HOFF, P. M.; CASTRO JR., G.bookPart Câncer de Cabeça e Pescoço(2013) CASTRO JUNIOR, Gilberto deconferenceObject EGFR GENOTYPING AND EPIDEMIOLOGY, CLINICAL AND PATHOLOGICAL FEATURES IN 191 PATIENTS WITH METASTATIC PULMONARY ADENOCARCINOMA IN SAO PAULO - BRAZIL.(2013) CASTRO JR., Gilberto; TAKAHASHI, Tiago K.; CAIRES-LIMA, Rafael; PROTASIO, Bruno M.; MAIA, Manuel C. D. F.; SOARES, Ibere C.; ROITBERG, Felipe S. R.; MARINI, Andrea M.; MARTINS, Renata E.; TAKAGAKI, Teresa Y.; ARAUJO, Pedro H. X. N.; TERRA, Ricardo M.; SHIANG, Christina; SIQUEIRA, Sheila A. C.; MELLO, Evandro S.; ALVES, Venancio A.; HOFF, Paulo M.- In Reply to Olson(2013) CASTRO JR., Gilberto de; SNITCOVSKY, Igor Moises Longo
conferenceObject RANDOMIZED PHASE-3 TRIAL (INSPIRE) OF NECITUMUMAB PLUS CISPLATIN-PEMETREXED VERSUS CISPLATIN-PEMETREXED ALONE AS FIRST-LINE THERAPY IN STAGE IV NON-SQUAMOUS NSCLC(2013) PAZ-ARES, Luis; MEZGER, Jorg; CIULEANU, Tudor; FISCHER, Jurgen R.; PAWEL, Joachim Von; PROVENCIO, Mariano; KAZARNOWICZ, Andrzej; LOSONCZY, Gyoergy; CASTRO JR., Gilberto; SZCZESNA, Aleksandra; CRINO, Lucio; RECK, Martin; RAMLAU, Rodryg; ULSPERGER, Ernst; SCHUMANN, Christian; MIZIARA, Jose E.; LESSA, Alvaro; DEPENBROCK, Henrik; SOLDATENKOVA, Victoria; BALINT, Beatrix; HIRSCH, Fred R.; SOCINSKI, Mark A.bookPart Biologia molecular dos tumores de cabeça e pescoço(2013) CASTRO JUNIOR, Gilberto; SNITCOVSKY, Igor Moysés Longo; PASINI, Fátima SolangeconferenceObject Should all patients (pts) with advanced biliary cancers receive first-line treatment with cisplatin and gemcitabine (GC)?(2013) MIRANDA, Vanessa Costa; DIB-FARIA, Luiza; BRAGHIROLI, Maria Ignez Freitas Melro; SABBAGA, Jorge; SARAGIOTTO, Daniel Fernandes; CASTRO, Gilberto; HOFF, Paulo M.; RIECHELMANN, RachelconferenceObject AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER(2013) SCAGLIOTTI, Giorgio; CASTRO JR., Gilberto; KIYIK, Murat; RUBEN, Kowalyszyn; DEPPERMANN, Karl-Matthias; ARRIOLA, Edurne; BOSQUEE, Lionel; WILLEY, Richard G.; COSAERT, Jan; RECK, Martin- Osteonecrosis of the mandible associated with bevacizumab therapy(2013) SANTOS-SILVA, Alan Roger; ROSA, Giuliano Augusto Belizario; CASTRO JUNIOR, Gilberto de; DIAS, Reinaldo Brito; RIBEIRO, Ana Carolina Prado; BRANDAO, Thais BiancaBevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of osteonecrosis of the jaws associated with bevacizumab (without any association with bisphosphonates) have been reported. The aim of this article was to describe an original case of bevacizumab-related osteonecrosis of the jaw. A 61-year-old man diagnosed with advanced renal cell carcinoma was undergoing treatment with intravenous bevacizumab and temsirolimus when he spontaneously developed mandible osteonecrosis, which resolved after 3 months of conservative management. The present case reinforces recent speculation that the anti-angiogenic properties of bevacizumab may represent a potential new source of osteonecrosis of the jaws in patients undergoing cancer treatment. Multidisciplinary teams in cancer care should be aware of the possible association between osteonecrosis of the jaw and bevacizumab therapy.